Xenon Pharmaceuticals Inc. (XENE)

37.65 -0.50 (-1.31%) At close: 04:00PM EST

Xenon Pharmaceuticals Inc.

3650 Gilmore Way
Suite 200
Burnaby, BC V5G 4W8
Canada

https://www.xenon-pharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 149

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA	Pres, CEO & Director	957.16k	N/A	1976
Ms. Sherry Aulin	Chief Financial Officer	458.64k	N/A	1984
Dr. Christopher John Kenney M.D.	Chief Medical Officer	494.83k	N/A	1971
Ms. Jodi Regts M.B.A., B.A., MBA	VP of Corp. Affairs & Investor Relations	N/A	N/A	N/A
Ms. Andrea DiFabio J.D.	Chief Legal Officer & Corp. Sec.	N/A	N/A	1968
Ms. Shelley McCloskey B.A.	Exec. VP of HR	N/A	N/A	1960
Dr. Robin P. Sherrington Ph.D.	Exec. VP of Strategy & Innovation	N/A	N/A	1961
Dr. James R. Empfield Ph.D.	Exec. VP of Drug Discovery	N/A	N/A	1961
Ms. Sheila M. Grant M.B.A., M.Sc., MBA	Exec. VP of R&D Operations	N/A	N/A	N/A
Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D.	Chief Commercial Officer	N/A	N/A	1979

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Corporate governance

Xenon Pharmaceuticals Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.